606 completed, 152 active not recruiting, 130 terminated, 117 recruiting. 1114 Phase 2, 145 Phase 1, 45 Phase 3.
Follow AstraZeneca: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies. CT204V-CD19 × CD20 - Relapsed or Refractory B-Cell Malignancies | Phase 1 / Phase 2 | Not yet recruiting | AstraZeneca | 160 | 2026-11-09 | 2026-11-12 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-11-01 | 2026-11-04 |
| Saruparib in HRDsig+ Solid Tumors Saruparib, FoundationOne®CDx - Malignant Neoplastic Disease (Disorder) | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 124 | 2026-11-01 | 2026-11-02 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer Fam-Trastuzumab Deruxtecan-Nxki - Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 27 | 2026-10-01 | 2026-10-01 |
| The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 Durvalumab, Monalizumab, Oleclumab - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Montefiore Medical Center | 52 | 2026-09-01 | 2026-06-09 |
| A Phase 2 Study of ABSK043 Combined With Osimertinib ABSK043 in combination with Osimertinib - Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive | Phase 2 | Not yet recruiting | Abbisko Therapeutics Co, Ltd | 72 | 2026-08-31 | 2026-07-17 |
| A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus Anifrolumab + APFS - Systemic Lupus Erythematosus | Phase 2 | Recruiting | AstraZeneca | 24 | 2026-08-31 | 2026-10-28 |
| Rash & Diarrhea Prophylaxis With Capivasertib Capivasertib, Loperamide, Fulvestrant - Metastatic HR+/HER2- Breast Cancer | Phase 2 | Recruiting | Maryam Lustberg | 108 | 2026-08-15 | 2026-07-29 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2 - RSV Respiratory Syncytial Virus | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 164 | 2026-07-08 | 2026-10-29 |
| TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma Durvalumab - Esophagogastric Adenocarcinoma | Phase 2 | Not yet recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 101 | 2026-07-01 | 2026-04-02 |
| A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization AZD0292, Placebo - Bronchiectasis With Pseudomonas Aeruginosa Colonization | Phase 2 | Recruiting | AstraZeneca | 84 | 2026-06-24 | 2026-10-08 |
| Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation Pentoxifylline, Placebo, α-Tocopherol - Non-Small Cell Lung Cancer, Radiation Induced Lung Injury (RILI) | Phase 2 | Recruiting | University Health Network, Toronto | 150 | 2026-06-15 | 2026-08-06 |
| A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM Eplontersen, ALXN2220, Placebo - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Phase 2 | Active not recruiting | AstraZeneca | 326 | 2026-06-11 | 2026-07-14 |
| A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | AstraZeneca | 359 | 2026-06-11 | 2026-10-29 |
| MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab Acalabrutinib, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | AstraZeneca | 80 | 2026-06-04 | 2026-10-23 |
| Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer AZD2265 (FPI-2265), Palacaparib (AZD9574), Docetaxel - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 152 | 2026-06-03 | 2026-10-14 |
Showing 20 of 1114. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (118) · Breast Neoplasms (96) · Lung Neoplasms (51) · Pulmonary Disease, Chronic Obstructive (51) · Diabetes Mellitus, Type 2 (46) · Neoplasms (40) · Prostatic Neoplasms (39) · Ovarian Neoplasms (37) · Neoplasm Metastasis (35) · Asthma (34) · Colorectal Neoplasms (33) · Triple Negative Breast Neoplasms (22) · Stomach Neoplasms (21) · Pancreatic Neoplasms (20) · Urinary Bladder Neoplasms (20)
durvalumab (219) · olaparib (90) · tremelimumab (75) · Gefitinib (74) · Carboplatin (56) · Cisplatin (50) · osimertinib (42) · Paclitaxel (40) · acalabrutinib (35) · Fulvestrant (34) · dapagliflozin (32) · Gemcitabine (30) · trastuzumab deruxtecan (30) · AZD 6244 (27) · Radiotherapy (25)
United States (598) · United Kingdom (238) · Canada (197) · Spain (195) · Germany (183) · France (162) · Italy (144) · South Korea (139) · Japan (129) · Poland (121) · Australia (106) · Netherlands (96) · Taiwan (83) · Hungary (82) · Denmark (78)
Lisa Porter, MD (9) · Esther Garcia, MD (8) · Jane Robertson, BSc, MBCHB, MD (6) · Bror Jonzon (4) · James Malone, MD (4) · Jane Robertson (4) · Lillian Siu, MD (4)
PMID 35170751, PMID 26961146, PMID 19238149, PMID 23922302, PMID 26589105, PMID 26894924, PMID 34510411, PMID 17705687, PMID 18753666, PMID 21079055, PMID 22212857, PMID 22236356, PMID 22795280, PMID 23001587, PMID 23831734, PMID 24126931, PMID 24432712, PMID 25287629, PMID 25660356, PMID 27461213, PMID 29293889, PMID 30512189, PMID 31345012, PMID 32027845, PMID 33254235, PMID 34089147, PMID 34383954, PMID 34904813, PMID 35713300, PMID 37185961, PMID 37490693, PMID 38018702, PMID 38504437, PMID 38729567, PMID 38770818, PMID 39695768, PMID 40311309, PMID 40461100, PMID 41212474, PMID 42208007, PMID 16179100, PMID 16204015, PMID 17166340, PMID 17296644, PMID 17298834, PMID 17563856, PMID 17595353, PMID 17985985, PMID 18018771, PMID 18300255
2023 (37), 2018 (19), 2019 (19), 2017 (17), 2025 (14), 2014 (12), 2015 (12), 2016 (12), 2008 (6), 2009 (3), P30CA015704 (3), 2005 (2), P30CA006516 (2), 1UH3TR001372-01 (1), 2004 (1)